These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26104577)

  • 1. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis.
    Cao X; Ye Q; Orlowski RZ; Wang X; Loghavi S; Tu M; Thomas SK; Shan J; Li S; Qazilbash M; Yin CC; Weber D; Miranda RN; Xu-Monette ZY; Medeiros LJ; Young KH
    J Hematol Oncol; 2015 Jun; 8():74. PubMed ID: 26104577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating low CD4
    Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
    Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extramedullary Waldenström macroglobulinemia.
    Banwait R; Aljawai Y; Cappuccio J; McDiarmid S; Morgan EA; Leblebjian H; Roccaro AM; Laubach J; Castillo JJ; Paba-Prada C; Treon S; Redd R; Weller E; Ghobrial IM
    Am J Hematol; 2015 Feb; 90(2):100-4. PubMed ID: 25349134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
    Eleutherakis-Papaiakovou E; Kastritis E; Gavriatopoulou M; Christoulas D; Roussou M; Ntanasis-Stathopoulos I; Kanellias N; Papatheodorou A; Dimopoulos MA; Terpos E
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):431-437. PubMed ID: 29685422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High plasma D-dimer level is a poor prognostic factor for patients with waldenström macroglobulinemia.
    Cao X; Kong YL; Wang L; Zhu HY; Liang JH; Xia Y; Fan L; Shi WY; Liu H; Li JY; Xu W
    Leuk Lymphoma; 2020 May; 61(5):1140-1146. PubMed ID: 31928271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].
    Tao Y; Wang S; Wang L; Wu M; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):993-997. PubMed ID: 35045669
    [No Abstract]   [Full Text] [Related]  

  • 7. Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience.
    Liu Z; Jiang S; Gu J; Liu H; Song G; Cao X
    Ann Hematol; 2023 Jan; 102(1):167-174. PubMed ID: 36374339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Durot E; Tomowiak C; Michallet AS; Dupuis J; Hivert B; Leprêtre S; Toussaint E; Godet S; Merabet F; Van Den Neste E; Ivanoff S; Roussel X; Zini JM; Regny C; Lemal R; Sutton L; Perrot A; Le Dû K; Kanagaratnam L; Morel P; Leblond V; Delmer A
    Br J Haematol; 2017 Nov; 179(3):439-448. PubMed ID: 28770576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.
    Guidez S; Labreuche J; Drumez E; Ysebaert L; Bakala J; Delette C; Hivert B; Protin C; Declercq H; Verlay M; Marolleau JP; Duhamel A; Morel P;
    Blood Adv; 2018 Nov; 2(22):3102-3111. PubMed ID: 30455359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenström macroglobulinemia.
    Chen J; Jia MN; Cai H; Li ZP; Li J; Zhou DB; Cao XX
    Ann Hematol; 2024 Sep; 103(9):3667-3675. PubMed ID: 38448788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.
    Saito A; Isoda A; Kojima M; Yokohama A; Tsukune Y; Sasaki M; Ito S; Ohtsu A; Koike M; Murayama K; Moriya K; Tamura H; Matsumoto M; Nakahashi H; Tanosaki S; Sakura T; Kawamura T; Miyanaga T; Nakamura N; Murakami H; Handa H; Tsukamoto N
    Int J Hematol; 2017 Nov; 106(5):681-690. PubMed ID: 28687991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
    Dhodapkar MV; Jacobson JL; Gertz MA; Rivkin SE; Roodman GD; Tuscano JM; Shurafa M; Kyle RA; Crowley JJ; Barlogie B
    Blood; 2001 Jul; 98(1):41-8. PubMed ID: 11418461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia.
    Yi S; Cui R; Li Z; An G; Qi J; Zou D; Zhang P; Chen H; Wang J; Chang H; Qiu L
    Chin Med J (Engl); 2014; 127(12):2327-31. PubMed ID: 24931251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.
    Cao X; Medeiros LJ; Xia Y; Wang X; Thomas SK; Loghavi S; Li X; Shah JJ; Gustafson SA; Weber DM; Miranda RN; Xu-Monette ZY; Orlowski RZ; Young KH
    Leuk Lymphoma; 2016 May; 57(5):1104-13. PubMed ID: 26421453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the presence and number of chromosomal abnormalities on the clinical outcome in Waldenström Macroglobulinemia: a monocentric experience.
    Danesin N; Bonaldi L; Martines A; Nalio S; Bertorelle R; Compagno S; Marcato R; Manni S; Scarmozzino F; Pizzi M; Tos APD; Cellini A; Scapinello G; Visentin A; Trentin L; Piazza F
    Ann Hematol; 2024 Aug; 103(8):2961-2968. PubMed ID: 38687347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact.
    Krzisch D; Guedes N; Boccon-Gibod C; Baron M; Bravetti C; Davi F; Armand M; Smagghe L; Caron J; Bernard OA; Susin S; Chapiro E; Leblond V; Nguyen-Khac F; Roos-Weil D;
    Am J Hematol; 2021 Dec; 96(12):1569-1579. PubMed ID: 34462944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia.
    Ahn A; Park CJ; Cho YU; Jang S; Seo EJ; Lee JH; Yoon DH; Suh C
    Ann Lab Med; 2020 May; 40(3):193-200. PubMed ID: 31858758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Waldenström macroglobulinemia. Experience in 31 patients].
    Cardemil D; León P; Peña C; Valladares X; Cabrera ME
    Rev Med Chil; 2019 Mar; 147(3):275-280. PubMed ID: 31344163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial Evaluation of the Patient with Waldenström Macroglobulinemia.
    Castillo JJ; Treon SP
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):811-820. PubMed ID: 30190019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
    Castillo JJ; Gustine JN; Keezer A; Meid K; Flynn CA; Dubeau TE; Chan G; Chen J; Demos MG; Guerrera ML; Jimenez C; Kofides A; Liu X; Munshi M; Tsakmaklis N; Patterson CJ; Xu L; Yang G; Hunter ZR; Treon SP
    Am J Hematol; 2020 Apr; 95(4):372-378. PubMed ID: 31868242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.